パーキンソン病治療市場：治療タイプ別、投与経路別、流通チャネル別、地域別、機会、予測、2017年～2031年

世界のパーキンソン病（PD）治療の市場規模は、予測期間の2024年～2031年に7.40％のCAGRで拡大し、2023年の49億8,000万米ドルから2031年には88億2,000万米ドルに成長すると予測されています。同市場は、規制当局の承認やパーキンソン病の市場参入企業の牽引力の高まりなど、いくつかの推進力により、予測期間中に有名なペースで成長すると予測されています。

パーキンソン病市場は常に変化しており、医薬品開発分野における進歩、ヘルスケアコストの上昇、疾患自体に対する理解の高まりなどが市場を形成しています。パーキンソン病は進行性の退行性神経疾患であり、振戦、固縮、徐脈などの症状を特徴とし、主に運動に影響を及ぼします。治療オプションにおける最近の技術革新が、市場を大いに活性化させています。疾患プロセスにおける特定の経路を標的とする新薬が登場し、効果的な治療レジメンがもたらされています。

加えて、特に発展途上諸国におけるヘルスケア支出の増加により、これらの治療へのアクセスが向上しています。また、各国政府は新規治療法を発見するための研究イニシアチブに投資しており、これが市場のさらなる成長に拍車をかけるとみられています。先進的な診断ツールは、病気の早期発見を可能にし、治療が早期に開始され、患者の予後改善につながることを意味します。市場には、治療費の高さや、特に中低所得国における病気に対する無知など、いくつかの障壁が残っています。疾患修飾療法が提供されていないことや、利用可能な治療に関連する様々な副作用は、患者のコンプライアンス、ひいては市場全体の成長にとって大きな制約となる可能性があります。

当レポートでは、世界のパーキンソン病治療市場について調査し、市場の概要とともに、治療タイプ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のパーキンソン病治療市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 治療タイプ別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 北米のパーキンソン病治療市場の見通し、2017年～2031年

第6章 欧州のパーキンソン病治療市場の見通し、2017年～2031年

第7章 アジア太平洋のパーキンソン病治療市場の見通し、2017年～2031年

第8章 南米のパーキンソン病治療市場の見通し、2017年～2031年

第9章 中東・アフリカのパーキンソン病治療市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場参入企業トップ10の情勢
  • GlaxoSmithKline plc
  • Novartis AG
  • AbbVie, Inc.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • Amneal Pharmaceuticals LLC
  • Britannia Pharmaceuticals Limited
  • Boehringer Ingelheim International GmbH
  • H. Lundbeck A/S
  • Supernus Pharmaceuticals, Inc.

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 3. Global Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 4. Global Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 5. Global Parkinson's Disease Treatment Market Share (%), By Region, 2017-2031F
• Figure 6. North America Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 8. North America Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 9. North America Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 10. North America Parkinson's Disease Treatment Market Share (%), By Country, 2017-2031F
• Figure 11. United States Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 13. United States Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 14. United States Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 15. Canada Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 17. Canada Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 18. Canada Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 19. Mexico Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 21. Mexico Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 22. Mexico Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23. Europe Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 25. Europe Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 26. Europe Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Europe Parkinson's Disease Treatment Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 30. Germany Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 31. Germany Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 32. France Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 34. France Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 35. France Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 36. Italy Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 38. Italy Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 39. Italy Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 40. United Kingdom Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 42. United Kingdom Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 43. United Kingdom Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44. Russia Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 46. Russia Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 47. Russia Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 48. Netherlands Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 50. Netherlands Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 51. Netherlands Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Spain Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 54. Spain Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 55. Spain Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 56. Turkey Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 58. Turkey Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 59. Turkey Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 60. Poland Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 62. Poland Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 63. Poland Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. South America Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 66. South America Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 67. South America Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 68. South America Parkinson's Disease Treatment Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 71. Brazil Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 72. Brazil Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 73. Argentina Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 75. Argentina Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 76. Argentina Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 77. Asia-Pacific Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 79. Asia-Pacific Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 80. Asia-Pacific Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 81. Asia-Pacific Parkinson's Disease Treatment Market Share (%), By Country, 2017-2031F
• Figure 82. India Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 84. India Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 85. India Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 86. China Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 88. China Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 89. China Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 90. Japan Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 92. Japan Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 93. Japan Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. Australia Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 96. Australia Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 97. Australia Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 98. Vietnam Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 100. Vietnam Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 101. Vietnam Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 102. South Korea Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 104. South Korea Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 105. South Korea Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 106. Indonesia Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 108. Indonesia Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 109. Indonesia Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 110. Philippines Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 112. Philippines Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 113. Philippines Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 114. Middle East & Africa Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 116. Middle East & Africa Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 117. Middle East & Africa Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 118. Middle East & Africa Parkinson's Disease Treatment Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 121. Saudi Arabia Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 122. Saudi Arabia Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 123. UAE Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 125. UAE Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 126. UAE Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 127. South Africa Parkinson's Disease Treatment Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Parkinson's Disease Treatment Market Share (%), By Treatment Type, 2017-2031F
• Figure 129. South Africa Parkinson's Disease Treatment Market Share (%), By Route of Administration, 2017-2031F
• Figure 130. South Africa Parkinson's Disease Treatment Market Share (%), By Distribution Channel, 2017-2031F
• Figure 131. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global Parkinson's disease (PD) treatment market is projected to witness a CAGR of 7.40% during the forecast period 2024-2031, growing from USD 4.98 billion in 2023 to USD 8.82 billion in 2031. The market is anticipated to thrive at a renowned pace during the forecast period owing to several driving forces like regulatory approvals, and growing traction from market players in Parkinson's disease.

The market of Parkinson's disease is constantly changing advances in the field of drug development, rising healthcare costs, and a growing understanding of the disease itself all shape the market. Parkinson's is a progressive degenerative neurological disorder that mostly affects movement, characterized by symptoms like tremors, rigidity, and bradykinesia. Recent innovation in therapeutic options has truly fueled the market. New drugs targeting specific pathways in the disease process have emerged, bringing out effective treatment regimens. In addition, augmenting healthcare spending, especially in developing countries, opens better access to these treatments. Also, governments are investing in research initiatives to discover novel therapies, and this will spur further growth in the market. The advanced diagnostic tools allow for diseases to be detected in the early stages, meaning that treatment might start early and, thus, lead to better outcomes for patients. There remain some barriers within the market, including the costliness of treatment and ignorance about the disease, especially in low and middle-income countries. Lack of provision of disease-modifying therapies and various adverse effects related to the available treatments can be a significant constraint in patient compliance and, by extension, overall market growth. Regular innovations and product launches maintain the market activeness and ensure the growth of the market, for instance, in May 2024, BIAL Holding, S.A. announced the launch of KYNMOBI (apomorphine hydrochloride), the first sublingual film approved in Germany for the treatment of OFF episodes in adult Parkinson's disease patients not sufficiently controlled by oral medication. The new formulation provides an effective on-demand therapy for OFF periods and motor fluctuations.

Rising Prevalence of Parkinson's Diseases

Parkinson's disease is the second most common neurodegenerative disorder globally, mostly occurring in the elderly population. The prevalence of Parkinson's is on the rise which led to heightened demand for treatment products. The dramatic rise in Parkinson's prevalence is straining healthcare systems and increasing the demand for medications, therapies, and surgical treatments. The combined direct and indirect costs of Parkinson's in the U.S. are estimated at nearly USD 52 billion per year. According to an article published in Frontiers in Neurology in May 2024, the global prevalence of Parkinson's disease was 6.1 million in 2016, and 8.5 million in 2019, and the prevalence is projected to go over 17 million in 2040. As the Parkinson's pandemic continues to grow, the need for expanded access to treatments, improved therapies, and ultimately a cure will only intensify in the coming years. While there is no cure for Parkinson's disease, another factor contributing to the high revenue generation for this market is the continuous need for medication for the patients.

Growing Investment in PD to Increase Market Growth

Neurodegenerative disease has been an active field of research including Parkinson's disease. The growing traction from market players and research promotors in this field is expected to contribute for the expansion of the Parkinson's disease treatment market. The research efforts from various organizations like The Michael J. Fox Foundation for Parkinson's Research, The Parkinson's Foundation, and others are significantly impacting the market scenario. For instance, in November 2023, PhotoPharmics, a leader in Parkinson's disease research and treatment, announced the successful first close of a USD 16 million investment round. The investment round marks a significant milestone in PhotoPharmics' mission to revolutionize Parkinson's disease treatment. The primary purpose of this investment round is to fund a pivotal clinical trial aimed at obtaining FDA market authorization for Celeste, PhotoPharmics' FDA breakthrough therapeutic device for Parkinson's disease. In another such example, Parkinson's UK invested USD 1.38 million in Mission Therapeutics Ltd's clinical trial through their Virtual Biotech program to help test a potential treatment called MTX325 in people with Parkinson's.

Carbidopa-Levodopa Segment to Dominate the Parkinson's Disease Treatment Market

Carbidopa-levodopa is the most used medication for Parkinson's disease due to its effectiveness in addressing the motor symptoms associated with the condition, thus, contributing a major share in the Parkinson's disease treatment market. Carbidopa-levodopa is used in combination for its dopaminergic effect, several notable formulations are available in the market with this combination and frequent drug launches related to the combination are anticipated to expand the market share in the forecast period. For instance, In January 2024, AbbVie, Inc. launched PRODUODOPA in the European Union for treating advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia. PRODUODOPA is a first-and-only subcutaneous 24-hour infusion of levodopa-based therapy, providing continuous relief and extending the period of well-controlled symptoms.

North America Dominates Parkinson's Disease Treatment Market Share

North America is anticipated to be the dominating region in the Parkinson's disease treatment market during the assessment period owing to robust healthcare infrastructure that results in a high rate of diagnoses and subsequent treatment population. The concentration of leading market players like AbbVie in the region conjugated with enhanced emphasis on the prevalence of Parkinson's disease is quite high in North American countries such as the United States and the prevalence is anticipated to rise further in the future leading to further market expansion. According to the data of the Parkinson's Foundation, around one million people in the United States are living with Parkinson's disease and the number is expected to grow up to 1.2 million by 2030 making Parkinson's disease the second-most common neurodegenerative disease after Alzheimer's disease. The diagnosis rate of Parkinson's in the United States is nearly 90,000 people each year.

Future Market Scenario (2024-2031F)

The future of the Parkinson's disease market is held with the robust pipeline of products under clinical investigation which may come in the market in upcoming years. Market players like AbbVie, and Roche have promising drug candidates in the pipeline. Apart from the medications, various alternative therapies are being developed and investigated to relieve Parkinson's patients. These therapies focus on the restoration of mobility and normal body functions. One such example is neuroprosthesis, a promising corrective therapy designed and tested in November 2023, by neuroscientists from L'Institut national de la sante et de la recherche medicale (Inserm), Centre national de la recherche scientifique (CNRS) and Universite de Bordeaux in France, along with Swiss researchers and neurosurgeons, to improve the gait disorders associated with Parkinson's disease.

Key Players Landscape and Outlook

Several renowned players like AbbVie, Amneal Pharmaceuticals, and others are catering to the market for Parkinson's disease treatment. The market activity is highly evident through various mergers, acquisition and product launch deals going on among the market players. In recent times several notable deals like AbbVie's acquisition strategy and Amneal's collaboration to expand geographical presence has significantly expanded the market.

In December 2023, AbbVie Inc. and Cerevel Therapeutics Holdings, Inc. announced an agreement in which AbbVie will acquire Cerevel Therapeutics and its strong neuroscience pipeline. This pipeline includes multiple clinical-stage and preclinical candidates that have the potential to treat various diseases such as schizophrenia, Parkinson's disease, and mood disorders. The acquisition complements AbbVie's neuroscience portfolio and adds a wide range of potentially best-in-class assets that could improve standards of care for patients with psychiatric and neurological disorders where significant unmet needs exist.

In February 2024, Amneal Pharmaceuticals, Inc. announced an exclusive licensing agreement with Zambon Biotech SA, a part of the Zambon group, for the distribution of a novel oral formulation of carbidopa/levodopa extended-release capsules, known as IPX203, in the European Union, United Kingdom, and Switzerland. This medication is intended for the treatment of Parkinson's disease and is currently under review by the U.S. Food and Drug Administration. Zambon will be responsible for seeking regulatory approval and commercializing IPX203 in Europe.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Parkinson's Disease Treatment Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Treatment Type
    • 4.2.1.1. Drugs
      • 4.2.1.1.1. Carbidopa-Levodopa
      • 4.2.1.1.2. Dopamine Agonists
      • 4.2.1.1.3. MAO-B Inhibitors
      • 4.2.1.1.4. COMT inhibitors
      • 4.2.1.1.5. Anticholinergics
      • 4.2.1.1.6. Others
    • 4.2.1.2. Medical Devices
      • 4.2.1.2.1. Deep Brain Stimulation (DBS) Devices
      • 4.2.1.2.2. Carbidopa/Levodopa Enteral Suspension Delivery Devices
  • 4.2.2. Route of Administration
    • 4.2.2.1. Oral
    • 4.2.2.2. Transdermal
    • 4.2.2.3. Subcutaneous
    • 4.2.2.4. Intestinal Infusion
    • 4.2.2.5. Others
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Treatment Type
  • 4.3.2. Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Parkinson's Disease Treatment Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Treatment Type
    • 5.2.1.1. Drugs
      • 5.2.1.1.1. Carbidopa-Levodopa
      • 5.2.1.1.2. Dopamine Agonists
      • 5.2.1.1.3. MAO-B Inhibitors
      • 5.2.1.1.4. COMT inhibitors
      • 5.2.1.1.5. Anticholinergics
      • 5.2.1.1.6. Others
    • 5.2.1.2. Medical Devices
      • 5.2.1.2.1. Deep Brain Stimulation (DBS) Devices
      • 5.2.1.2.2. Carbidopa/Levodopa Enteral Suspension Delivery Devices
  • 5.2.2. Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Transdermal
    • 5.2.2.3. Subcutaneous
    • 5.2.2.4. Intestinal Infusion
    • 5.2.2.5. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Parkinson's Disease Treatment Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.1.1. Drugs
        • 5.3.1.2.1.1.1. Carbidopa-Levodopa
        • 5.3.1.2.1.1.2. Dopamine Agonists
        • 5.3.1.2.1.1.3. MAO-B Inhibitors
        • 5.3.1.2.1.1.4. COMT inhibitors
        • 5.3.1.2.1.1.5. Anticholinergics
        • 5.3.1.2.1.1.6. Others
        • 5.3.1.2.1.2. Medical Devices
        • 5.3.1.2.1.2.1. Deep Brain Stimulation (DBS) Devices
        • 5.3.1.2.1.2.2. Carbidopa/Levodopa Enteral Suspension Delivery Devices
      • 5.3.1.2.2. Route of Administration
        • 5.3.1.2.2.1. Oral
        • 5.3.1.2.2.2. Transdermal
        • 5.3.1.2.2.3. Subcutaneous
        • 5.3.1.2.2.4. Intestinal Infusion
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Distribution Channel
        • 5.3.1.2.3.1. Hospital Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Online Pharmacies
        • 5.3.1.2.3.4.
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Parkinson's Disease Treatment Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Parkinson's Disease Treatment Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Parkinson's Disease Treatment Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Parkinson's Disease Treatment Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. GlaxoSmithKline plc
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Novartis AG
  • 20.3.3. AbbVie, Inc.
  • 20.3.4. Merck & Co., Inc.
  • 20.3.5. Teva Pharmaceutical Industries Ltd
  • 20.3.6. Amneal Pharmaceuticals LLC
  • 20.3.7. Britannia Pharmaceuticals Limited
  • 20.3.8. Boehringer Ingelheim International GmbH
  • 20.3.9. H. Lundbeck A/S
  • 20.3.10. Supernus Pharmaceuticals, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer